Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02032771 · ClinicalTrials.gov registry record · NA
Impact of M22 Synergistic Sequential Treatment (SST)
A NA study, sponsored by Lumenis Be.
- Completed
- Registry status
- NA
- Development phase
- 33
- Enrollment target
NCT02032771 is a NA study that has completed, run by Lumenis Be. The registered enrollment target is 33 participants.
The verdict
NCT02032771, a NA study, has completed, sponsored by Lumenis Be.
- COMPLETED
- Registry status
- NA
- Development phase
- 33 participants
- Enrollment target
Study Summary
Up to 40 healthy subjects at 2 sites, age 30-65 year old with Fitzpatrick-Elastosis score of 3-6 and mild to moderate age/sun-related facial pigmentation that wish to improve their facial skin appearance. Hypothesis: The SST will improve the appearance of the wrinkles/elastosis and/or pigmentation by at least 1 on the FES scale or ≥50% in category scale at 3 months follow-ups in at least 50% of the study population.
Interventions
- DEVICE M22 IPL and ResurFX
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2014-01 |
| Est. Completion | 2016-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02032771
The ClinicalTrials.gov registry entry for NCT02032771 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lumenis Be, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which M22 IPL and ResurFX is the first listed.
NCT02032771 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02032771 about?
NCT02032771 is a clinical study titled "Impact of M22 Synergistic Sequential Treatment (SST)". Up to 40 healthy subjects at 2 sites, age 30-65 year old with Fitzpatrick-Elastosis score of 3-6 and mild to moderate age/sun-related facial pigmentation that wish to improve their facial skin appearance. Hypothesis: The SST will improve the appearance of the wrinkles/elastosis and/or pigmentation ...
What is the current status of trial NCT02032771?
This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2014-01. Estimated completion is 2016-02.
What interventions are being tested in trial NCT02032771?
The interventions under investigation include: M22 IPL and ResurFX (DEVICE).
Who is sponsoring clinical trial NCT02032771?
This trial is sponsored by Lumenis Be, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.